Self-Host
Tools / Inside Trading Tracker
Inside Trading Tracker
Track insider trading activity at publicly traded companies to understand how executives are trading their shares.
Amicus Therapeutics Inc. (FOLD) Insider Trading Activity
Healthcare • Biotechnology • 500 employees
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset. It has collaboration and license agreements with the University of Pennsylvania to research and develop parvovirus gene therapy products; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.
Total Value
-$3,094,696.85
Total Shares
653,809
Average Trade Value
-$75,480.41
Most Active Insider
Campbell Bradley L
Total Activity: $1,951,240
Largest Single Transaction
$676,704
by Campbell Bradley L on Feb 11, 2025
30-Day Activity
0 Transactions
Volume: 0 shares
Value: $0
|
Name
|
Position
|
Date
|
Shares
|
Value
|
Holdings
|
Type
|
|---|---|---|---|---|---|---|
|
President and CEO
|
Mar 15, 2025 | 13,375 | $119,038 | 1,137,282 (-1.2%) | Payment of Exercise Price | |
|
President and CEO
|
Feb 19, 2025 | 400 | $3,612 | 1,151,057 (+0.0%) | Exercise/Conversion | |
|
President and CEO
|
Feb 19, 2025 | 400 | $4,000 | 1,150,657 (-0.0%) | Sale | |
|
Chief Legal Officer
|
Feb 11, 2025 | 64,800 | $10,000 | 536,294 (+12.1%) | Grant | |
|
Chief People Officer
|
Feb 11, 2025 | 20,593 | $197,075 | 348,261 (-5.9%) | Payment of Exercise Price | |
|
Chief People Officer
|
Feb 11, 2025 | 52,338 | $10,000 | 368,854 (+14.2%) | Grant | |
|
Chief Development Officer
|
Feb 11, 2025 | 22,724 | $217,469 | 465,476 (-4.9%) | Payment of Exercise Price | |
|
President and CEO
|
Feb 11, 2025 | 137,075 | $10,000 | 1,220,768 (+11.2%) | Grant | |
|
President and CEO
|
Feb 11, 2025 | 70,711 | $676,704 | 1,150,657 (-6.1%) | Payment of Exercise Price | |
|
Chief Legal Officer
|
Feb 11, 2025 | 28,584 | $273,549 | 507,710 (-5.6%) | Payment of Exercise Price | |
|
Chief Development Officer
|
Feb 11, 2025 | 52,338 | $10,000 | 488,200 (+10.7%) | Grant | |
|
Chief Accounting Officer
|
Feb 11, 2025 | 13,500 | $129,195 | 109,441 (-12.3%) | Payment of Exercise Price | |
|
Chief Accounting Officer
|
Feb 11, 2025 | 27,416 | $10,000 | 122,941 (+22.3%) | Grant | |
|
Chief Development Officer
|
Jan 4, 2025 | 3,127 | $29,425 | 435,862 (-0.7%) | Payment of Exercise Price | |
|
Chief People Officer
|
Jan 4, 2025 | 2,692 | $25,332 | 316,516 (-0.9%) | Payment of Exercise Price | |
|
President and CEO
|
Jan 4, 2025 | 7,368 | $69,333 | 1,083,693 (-0.7%) | Payment of Exercise Price | |
|
Chief Accounting Officer
|
Jan 4, 2025 | 1,297 | $12,205 | 95,525 (-1.4%) | Payment of Exercise Price | |
|
Chief Legal Officer
|
Jan 4, 2025 | 3,381 | $31,815 | 471,494 (-0.7%) | Payment of Exercise Price | |
|
Chief Legal Officer
|
Jan 3, 2025 | 15,397 | $144,886 | 474,875 (-3.2%) | Payment of Exercise Price | |
|
Chief People Officer
|
Jan 3, 2025 | 69,228 | $0 | 331,195 (+20.9%) | Grant | |
|
Chief Legal Officer
|
Jan 3, 2025 | 112,495 | $0 | 490,272 (+22.9%) | Grant | |
|
Chief Development Officer
|
Jan 3, 2025 | 83,073 | $0 | 453,288 (+18.3%) | Grant | |
|
President and CEO
|
Jan 3, 2025 | 266,528 | $0 | 1,132,535 (+23.5%) | Grant | |
|
President and CEO
|
Jan 3, 2025 | 41,474 | $390,270 | 1,091,061 (-3.8%) | Payment of Exercise Price | |
|
Chief Development Officer
|
Jan 3, 2025 | 14,299 | $134,554 | 438,989 (-3.3%) | Payment of Exercise Price | |
|
Chief Accounting Officer
|
Jan 3, 2025 | 8,275 | $77,868 | 96,822 (-8.5%) | Payment of Exercise Price | |
|
Chief Accounting Officer
|
Jan 3, 2025 | 34,614 | $0 | 105,097 (+32.9%) | Grant | |
|
Chief Financial Officer
|
Jan 3, 2025 | 83,073 | $0 | 227,427 (+36.5%) | Grant | |
|
Chief People Officer
|
Jan 3, 2025 | 11,987 | $112,798 | 319,208 (-3.8%) | Payment of Exercise Price | |
|
Chief People Officer
|
Jan 2, 2025 | 5,381 | $50,097 | 261,967 (-2.1%) | Payment of Exercise Price | |
|
Chief Legal Officer
|
Jan 2, 2025 | 6,442 | $59,975 | 377,777 (-1.7%) | Payment of Exercise Price | |
|
Chief Financial Officer
|
Jan 2, 2025 | 7,482 | $69,657 | 144,354 (-5.2%) | Payment of Exercise Price | |
|
Chief Accounting Officer
|
Jan 2, 2025 | 3,443 | $32,054 | 70,483 (-4.9%) | Payment of Exercise Price | |
|
Chief Development Officer
|
Jan 2, 2025 | 6,990 | $65,077 | 370,215 (-1.9%) | Payment of Exercise Price | |
|
President and CEO
|
Jan 2, 2025 | 20,647 | $192,224 | 866,007 (-2.4%) | Payment of Exercise Price | |
|
President and CEO
|
Dec 2, 2024 | 7,500 | $64,575 | 894,154 (+0.8%) | Exercise/Conversion | |
|
President and CEO
|
Dec 2, 2024 | 7,500 | $75,125 | 886,654 (-0.8%) | Sale | |
|
President and CEO
|
Nov 6, 2024 | 7,901 | $97,024 | 894,555 (+0.9%) | Exercise/Conversion | |
|
President and CEO
|
Nov 6, 2024 | 7,901 | $98,800 | 886,654 (-0.9%) | Sale | |
|
President and CEO
|
Nov 1, 2024 | 7,500 | $85,960 | 886,654 (-0.8%) | Sale | |
|
President and CEO
|
Nov 1, 2024 | 7,500 | $64,575 | 894,154 (+0.8%) | Exercise/Conversion |